Your browser doesn't support javascript.
loading
Interrogation of a live-attenuated enterotoxigenic Escherichia coli vaccine highlights features unique to wild-type infection.
Chakraborty, Subhra; Randall, Arlo; Vickers, Tim J; Molina, Doug; Harro, Clayton D; DeNearing, Barbara; Brubaker, Jessica; Sack, David A; Bourgeois, A Louis; Felgner, Philip L; Liang, Xiaowu; Mani, Sachin; Wenzel, Heather; Townsend, R Reid; Gilmore, Petra E; Darsley, Michael J; Rasko, David A; Fleckenstein, James M.
Afiliación
  • Chakraborty S; 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA.
  • Randall A; 2Antigen Discovery, Inc. (ADI), Irvine, CA USA.
  • Vickers TJ; 3Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, Saint Louis, MO USA.
  • Molina D; 2Antigen Discovery, Inc. (ADI), Irvine, CA USA.
  • Harro CD; 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA.
  • DeNearing B; 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA.
  • Brubaker J; 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA.
  • Sack DA; 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA.
  • Bourgeois AL; 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA.
  • Felgner PL; 2Antigen Discovery, Inc. (ADI), Irvine, CA USA.
  • Liang X; 4Vaccine R & D Center, University of California, Irvine, Irvine, CA USA.
  • Mani S; 2Antigen Discovery, Inc. (ADI), Irvine, CA USA.
  • Wenzel H; 5Enteric Vaccine Initiative, PATH, Washington DC, USA.
  • Townsend RR; 5Enteric Vaccine Initiative, PATH, Washington DC, USA.
  • Gilmore PE; 6Department of Medicine, Divsion of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, USA.
  • Darsley MJ; 6Department of Medicine, Divsion of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, USA.
  • Rasko DA; MD Biologic Consulting Ltd, Cambridge, UK.
  • Fleckenstein JM; 8The Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD USA.
NPJ Vaccines ; 4: 37, 2019.
Article en En | MEDLINE | ID: mdl-31482013
ABSTRACT
Enterotoxigenic Escherichia coli (ETEC) infections are a common cause of severe diarrheal illness in low- and middle-income countries. The live-attenuated ACE527 ETEC vaccine, adjuvanted with double mutant heat-labile toxin (dmLT), affords clear but partial protection against ETEC challenge in human volunteers. Comparatively, initial wild-type ETEC challenge completely protects against severe diarrhea on homologous re-challenge. To investigate determinants of protection, vaccine antigen content was compared to wild-type ETEC, and proteome microarrays were used to assess immune responses following vaccination and ETEC challenge. Although molecular interrogation of the vaccine confirmed expression of targeted canonical antigens, relative to wild-type ETEC, vaccine strains were deficient in production of flagellar antigens, immotile, and lacked production of the EtpA adhesin. Similarly, vaccination ± dmLT elicited responses to targeted canonical antigens, but relative to wild-type challenge, vaccine responses to some potentially protective non-canonical antigens including EtpA and the YghJ metalloprotease were diminished or absent. These studies highlight important differences in vaccine and wild-type ETEC antigen content and call attention to distinct immunologic signatures that could inform investigation of correlates of protection, and guide vaccine antigen selection for these pathogens of global importance.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2019 Tipo del documento: Article